TY - JOUR
T1 - Validation of a predictive model for identifying an increased risk for recurrence in adolescents and young adults with a first provoked thromboembolism
AU - Limperger, Verena
AU - Torge, Antje
AU - Kiesau, Bettina
AU - Langer, Florian
AU - Kenet, Gili
AU - Mesters, Rolf
AU - Juhl, David
AU - Stoll, Monika
AU - Shneyder, Maria
AU - Kowalski, Dorothee
AU - Bajorat, Tido
AU - Rocke, Angela
AU - Kuta, Piotr
AU - Lasarow, Livia
AU - Spengler, Dietmar
AU - Junker, Ralf
AU - Nowak-Göttl, Ulrike
N1 - Publisher Copyright:
© 2022
PY - 2022/5
Y1 - 2022/5
N2 - Background: To develop and validate a predictive model to determinate patients at increased risk to suffer from recurrence following a first provoked deep vein thrombosis (VTE). Methods: Predictive variables, i.e. male sex [1 point], inherited thrombophilia (IT) status (none [0 points], single [1 point], combined variants [2 points]), blood group non-0, and age at first VTE onset were included into a risk assessment model, which was derived in 511 patients and then validated in 509 independent subjects. Results: VTE recurrence risk score (maximum 4 points, range 0–3) was below two for patients scored as low-risk (LRS) and ≥2 for patients at high-risk (HRS). Within a median time of 3 years after withdrawal of anticoagulation (AC) recurrence rate in LRG (derivation) was 11.8% versus 26.0% in HRS (p < 0.001). In the validation cohort within 2.2 years the recurrence rate was 9.8% in LRS versus 30.1% in HRS (p < 0.001). In multivariable analysis adjusted for age at first VTE and blood group the recurrent risk in HRS was significantly increased compared with the LRS (derivation: hazard/95% confidence interval: 3.7/1.75–7.91; validation: 4.7/2.24–9.81; combined 5.2/1.92–13.9). Model specificity (sensitivity) was 79.0% (52.0%) in the derivation cohort compared with 78.0% (43.0%) in the validation group. In conclusion, in the prediction model presented here the risk of VTE recurrence was associated with male gender and combined ITs. Based on the negative predictive value calculated the model may identify patients with a first provoked VTE not being at risk for recurrence.
AB - Background: To develop and validate a predictive model to determinate patients at increased risk to suffer from recurrence following a first provoked deep vein thrombosis (VTE). Methods: Predictive variables, i.e. male sex [1 point], inherited thrombophilia (IT) status (none [0 points], single [1 point], combined variants [2 points]), blood group non-0, and age at first VTE onset were included into a risk assessment model, which was derived in 511 patients and then validated in 509 independent subjects. Results: VTE recurrence risk score (maximum 4 points, range 0–3) was below two for patients scored as low-risk (LRS) and ≥2 for patients at high-risk (HRS). Within a median time of 3 years after withdrawal of anticoagulation (AC) recurrence rate in LRG (derivation) was 11.8% versus 26.0% in HRS (p < 0.001). In the validation cohort within 2.2 years the recurrence rate was 9.8% in LRS versus 30.1% in HRS (p < 0.001). In multivariable analysis adjusted for age at first VTE and blood group the recurrent risk in HRS was significantly increased compared with the LRS (derivation: hazard/95% confidence interval: 3.7/1.75–7.91; validation: 4.7/2.24–9.81; combined 5.2/1.92–13.9). Model specificity (sensitivity) was 79.0% (52.0%) in the derivation cohort compared with 78.0% (43.0%) in the validation group. In conclusion, in the prediction model presented here the risk of VTE recurrence was associated with male gender and combined ITs. Based on the negative predictive value calculated the model may identify patients with a first provoked VTE not being at risk for recurrence.
KW - Male sex
KW - Provoked thrombosis
KW - Recurrence
KW - Risk assessment model
KW - Thrombophilia
UR - http://www.scopus.com/inward/record.url?scp=85122801908&partnerID=8YFLogxK
U2 - 10.1016/j.bcmd.2022.102651
DO - 10.1016/j.bcmd.2022.102651
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35051688
AN - SCOPUS:85122801908
SN - 1079-9796
VL - 94
JO - Blood Cells, Molecules, and Diseases
JF - Blood Cells, Molecules, and Diseases
M1 - 102651
ER -